复星医药(600196.SH)：控股子公司药品获临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its injectable HLX43, a targeted antibody-drug conjugate (ADC) developed in collaboration with a new DNA topoisomerase I inhibitor [1] Group 1 - The HLX43 is a conjugate of a newly licensed small molecule toxin-peptide chain and an independently developed PD-L1 targeting antibody [1]